Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety follow-up of PRAME-directed TCR T cell therapy IMA203/IMA203CD8 in solid tumors
2026-525827-25-00Phase 2Authorised
- Sponsor
- Immatics
- Start
- Aug 2026
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of anzutresgene autoleucel and IMA203CD8 in Nonhematologic neoplasms, sponsored by Immatics. Primary endpoint: Number of patients with delayed adverse events. Planned start Aug 2026; status: authorised.
02
Drugs
anzutresgene autoleucelIMA203CD8
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2026-525827-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525827-25-00.